9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
220 articles with GlycoMimetics, Inc.
Discussion to focus on Phase 3 development plans for GMI-1271 in AML
GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy
GlycoMimetics, Inc. announced today that it has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) group to initiate clinical trial startup activities.
1/15/2018Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase I/II Trial for GMI-1271
This translational research provides important evidence that elucidates how treatment with GMI-1271 appears to be improving sensitivity to chemotherapy.
In an overall good year for pharma and biotech sectors, there have been some standouts.
As of September 30, 2017, GlycoMimetics had cash and cash equivalents of $112.9 million as compared to $40.0 million as of December 31, 2016.
GlycoMimetics announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017, at 8:30 a.m. ET.
GlycoMimetics Presents Updated Data From Ongoing Phase I/II Clinical Trial Of GMI-1271 In Patients With Acute Myeloid Leukemia At ASCO 2017 Annual Meeting
GlycoMimetics Announces Closing Of Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
GlycoMimetics, Inc. Announces Publication Of Preclinical Data Showing Role Of E-selectin Ligands In Multiple Myeloma